Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vebreltinib ADC (MRG003) + ICI + Radiotherapy in Advanced ESCC
NCT07892833Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Bengbu Medical University
- Start
- May 2026
- Primary completion
- May 2028
- Countries
- 1
01
Overview
A Phase 2 trial of becotatug vedotin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by First Affiliated Hospital of Bengbu Medical University. Started May 2026; status: recruiting.
02
Drugs
becotatug vedotin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07892833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07892833.